obecabtagene autoleucel (obe-cel)
Jump to navigation
Jump to search
Indications
- relapsed or refractory B-cell acute lymphoblastic leukemia (ALL)
* estimated 6- & 12-month event-free survival is 65.4% & 49.5%, respectively
* 6- & 12-month overall survival is 80.3% & 61.1%, respectively
* median overall survival is 15.6 months
Adverse effects
- >= grade 3 cytokine release syndrome (2.4%)
- >= grade 3 or higher immune effector cell-associated neurotoxicity syndrome (7.1%)
Mechanism of action
- authologous anti-CD19 CAR T-cell therapy which uses an intermediate-affinity chimeric antigen receptor (CAR) to reduce toxic effects & improve persistence
More general terms
References
- ↑ Bassett M New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show. Results of FELIX study supported obecabtagene autoleucel's recent FDA approval. MedPage Today November 27, 2024 https://www.medpagetoday.com/hematologyoncology/leukemia/113158
Roddie C, Sandhu KS, Tholouli E et al Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. N Engl J Med. 2024 Nov 27. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39602653 https://www.nejm.org/doi/full/10.1056/NEJMoa2406526